OncLive TV

Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.

Peter Kozuch, MD, discusses the phase 2/3 CIRCULATE-US trial evaluating chemotherapy decisions for patients with resected colorectal cancer based on circulating tumor DNA status.

Manmeet Singh Ahluwalia, MD, discusses the evaluation of SurVaxM in combination with oral temozolomide in patients with newly diagnosed glioblastoma.

Jeremy Force, DO, discusses the efficacy of trastuzumab deruxtecan in pretreated patients with HER2-positive breast cancer on the phase 3 DESTINY-Breast02 trial.

Sapna Patel, BA, MD, discusses the sequencing of immunotherapy and targeted therapy in BRAF-mutant melanoma.

Rupert Bartsch, MD, discusses interim findings produced from the real-world use of neratinib in select patients with hormone receptor-positive, HER2-overexpressed breast cancer.

Carsten Niemann, MD, PhD, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease in the peripheral blood from the phase 3 GLOW trial in patients with chronic lymphocytic leukemia.

Carlo Contreras, MD, discusses the role of neoadjuvant pembrolizumab for the treatment of patients with desmoplastic melanoma.

Jeanny B. Aragon-Ching, MD, FACP, discusses the use of maintenance avelumab as the standard-of-care treatment for patients with locally advanced or metastatic urothelial carcinoma.

Maryam Lustberg, MD, MPH, discusses the real-world use of ovarian suppression therapy in clinical practice for premenopausal patients with hormone receptor-positive, HER2-positive breast cancer.

Megan Kruse, MD, discusses how socioeconomic disparities and access to health insurance can contribute to poorer overall survival (OS) outcomes in adolescent patients with invasive breast cancer.

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.

Claire F. Verschraegen, MD, discusses the need for predictive biomarkers for the use of immunotherapy in the treatment of melanoma.

Jane L. Meisel, MD, discusses the effect of the HER2-low classification for patients with breast cancer.

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

Vamsidhar Velcheti, MD, discusses the evaluation of immunotherapy combination regimens for patients with metastatic non–small cell lung cancer.

Al-Ola A. Abdallah, MD, discusses interim results from an ongoing phase 1 trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma.

Carmelo Carlo-Stella, MD, PhD, discusses updated results from a phase 1 dose-escalation study of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss second-line treatment options for patients with non—small cell lung cancer who progressed on first-line EGFR-directed tyrosine kinase inhibitors.

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer.

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the use of antibody-drug conjugates (ADCs) in HER2-mutated non–small cell lung cancer.

Paolo Tarantino, MD, discusses the impact of the phase 3 DESTINY-Breast04 trial in the treatment of HER2-low breast cancer.

Elias Jabbour, MD, discusses the evaluation of olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Michelle Shiller, DO, AP/CP, MGP, discusses the role of trastuzumab deruxtecan in patients with HER2-positive breast cancer.

Shaji Kumar, MD, discusses the updated data from the phase 3 MAIA trial in newly diagnosed multiple myeloma.

Stephen T. Oh, MD, PhD, discusses the anemia benefit of pacritinib in patients with myelofibrosis.

Gopa Iyer, MD, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.